Post-exposure prophylaxis for HIV infection in gay and bisexual men - Implications for the future of HIV prevention

被引:40
作者
Kalichman, SC [1 ]
机构
[1] Med Coll Wisconsin, Ctr AIDS Intervent Res, Milwaukee, WI 53226 USA
关键词
prophylaxis; retrovirus infections; HIV infections; prevention and control;
D O I
10.1016/S0749-3797(98)00037-3
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Objective: To assess the psychological and behavioral characteristics of gay and bisexual men who intend to we antiretroviral post-exposure prophylaxis (PEP) to prevent HIV infection. Methods: Gay and bisexual men who had not tested HIV seropositive and were not in long-term exclusive sexual relationships (n = 327) completed anonymous surveys consisting of demographic characteristics, gay community acculturation, experience with and attitudes toward PEP, substance use, and sexual behavior in the past 6 months. Setting: A large annual Gay Pride festival in Atlanta, Georgia. Results: There were 8 (3%) men who had already used PEP and 85 (26%) who planned to use PEP to prevent themselves from becoming HIV infected. Compared to the 242 (74%) men who did not indicate plans to use PEP, those planning to use PEP were younger, less well educated, more likely to have used illicit substances in the past 6 months, and were more likely to have a history of injection drug use. Men intending to use PEP were also more likely to have practiced unprotected anal and oral intercourse as the receptive partner and were more likely to have multiple anal intercourse partners with whom they were receptive. Conclusions: Gay and bisexual men are generally supportive of the immediate use of PEP and a significant number of men are planning to use PEP, particularly less educated men who use multiple substances and practice the highest-risk sexual behaviors. Concurrent behavioral interventions must, therefore, be considered critical in the advancement of PEP.
引用
收藏
页码:120 / 127
页数:8
相关论文
共 18 条
[1]   Protease inhibitors in the homeless [J].
Bangsberg, D ;
Tulsky, JP ;
Hecht, FM ;
Moss, AR .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 278 (01) :63-65
[2]  
*CDC, 1995, MMWR-MORBID MORTAL W, V44, P929
[3]  
COX S, 1997, POSITIVELY AWARE MAY
[4]   HIV-1 protease inhibitors - A review for clinicians [J].
Deeks, SG ;
Smith, M ;
Holodniy, M ;
Kahn, JO .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (02) :145-153
[5]  
FRUTCHEY C, 1995, UNPUB ABILITY ENVISI
[6]  
*GA DIV PUBL HLTH, 1996, HIV AIDS SURV REP
[7]  
HICKSON F, 1997, AIDS, V10, P771
[8]  
Ho DD, 1996, B NEW YORK ACAD MED, V73, P37
[9]  
HOWARD D, 1997, SO VOICE 0403, P10
[10]  
Kalichman SC, 1997, AIDS EDUC PREV, V9, P41